2 September 2016 - This time, a story in The Economist on how the row over Mylan’s EpiPen allergy medicine is raising fresh questions about how medicines are priced in the US.

Julaina Keeping is rushing to work in Oklahoma with two children in tow. Her three-year-old son, Eli, has cystic fibrosis, a deadly lung disorder. He is too young for a drug called Orkambi from Vertex Pharmaceuticals, a biotech firm, but one day it may keep him alive. His mother’s question is why it costs over $250,000. A charity helped pay for its development, she says, with some donations from people who were “D-Y-I-N-G”—she spells out the word. That is because she doesn’t want her other child to understand. “She doesn’t know her brother’s disease is F-A-T-A-L.”

Read The Economist article